Overview

Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies

Status:
Terminated
Trial end date:
2015-11-12
Target enrollment:
Participant gender:
Summary
To estimate the maximum tolerated dose (MTD) or recommended dose for phase II (RP2D) of CLR457 and to investigate the anti-tumor activity of CLR457
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals